Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, Histopathology, vol.154, issue.1, pp.113-130, 2007. ,
DOI : 10.1016/S0002-9440(10)65436-3
Hereditary Colorectal Cancer, New England Journal of Medicine, vol.348, issue.10, pp.919-932, 2003. ,
DOI : 10.1056/NEJMra012242
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines, Cancer research, vol.57, pp.808-811, 1997. ,
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability, Cancer research, vol.58, pp.3455-3460, 1998. ,
The Frequency of Hereditary Defective Mismatch Repair in a Prospective Series of Unselected Colorectal Carcinomas, The American Journal of Human Genetics, vol.69, issue.4, pp.780-790, 2001. ,
DOI : 10.1086/323658
Features of Colorectal Cancers with High-Level Microsatellite Instability Occurring in Familial and Sporadic Settings, The American Journal of Pathology, vol.159, issue.6, pp.2107-2116, 2001. ,
DOI : 10.1016/S0002-9440(10)63062-3
Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases, British Journal of Cancer, vol.93, issue.9, pp.1746-1753, 2005. ,
DOI : 10.1002/(SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.3.CO;2-S
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies, Clinical Cancer Research, vol.20, issue.20, pp.5322-5330, 2014. ,
DOI : 10.1158/1078-0432.CCR-14-0332
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status, Nature, vol.18, issue.6901, pp.934-934, 2002. ,
DOI : 10.1073/PNAS.261714699
BRAF Mutations in Colon Cancer Are Not Likely Attributable to Defective DNA Mismatch Repair, Cancer Res, vol.63, pp.5209-5212, 2003. ,
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes, Oncogene, vol.23, issue.24, pp.3995-3998, 2005. ,
DOI : 10.1002/gcc.10310
Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer, Familial Cancer, vol.89, issue.23, pp.301-310, 2007. ,
DOI : 10.1016/S0002-9440(10)63062-3
BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer, International Journal of Cancer, vol.121, issue.7, pp.1624-1630, 2013. ,
DOI : 10.1053/gast.2001.29616
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial, Annals of Oncology, vol.26, issue.1 ,
DOI : 10.1093/annonc/mdu499
Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab, JAMA Oncology, vol.2, issue.5, p.643, 2016. ,
DOI : 10.1001/jamaoncol.2015.5225
URL : https://hal.archives-ouvertes.fr/hal-01427989
The consensus molecular subtypes of colorectal cancer, Nature Medicine, vol.228, issue.11 ,
DOI : 10.1186/gb-2004-5-10-r80
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2520 ,
DOI : 10.1056/NEJMoa1500596
Programmed death-1 blockade in mismatch repair deficient colorectal cancer, Journal of Clinical Oncology, vol.34, 2016. ,
Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI- H): CheckMate-142 interim results, Journal of Clinical Oncology, vol.34, 2016. ,
Mechanisms and functions of DNA mismatch repair, Cell Research, vol.62, issue.1, pp.85-98, 2008. ,
DOI : 10.1126/science.7761852
Mismatch repair deficient colorectal cancer in the era of personalized treatment, Nature Reviews Clinical Oncology, vol.24, issue.4, pp.197-208, 2010. ,
DOI : 10.1172/JCI19757
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC???, Gastroenterology, vol.116, issue.6 ,
DOI : 10.1016/S0016-5085(99)70510-X
Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability, JNCI Journal of the National Cancer Institute, vol.96, issue.4, pp.261-268, 2004. ,
DOI : 10.1093/jnci/djh034
Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.35, pp.5783-5788, 2008. ,
DOI : 10.1200/JCO.2008.17.5950
Identification of Lynch Syndrome Among Patients With Colorectal Cancer, JAMA, vol.308, issue.15, pp.1555-2012 ,
DOI : 10.1001/jama.2012.13088
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts, Gut, vol.62, issue.6, pp.812-823, 2013. ,
DOI : 10.1136/gutjnl-2012-304356
Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database, Journal of Clinical Oncology, vol.32, p.5, 2014. ,
Lynch or Not Lynch? Is that Always a Question?, Adv Cancer Res, vol.113, pp.121-166 ,
DOI : 10.1016/B978-0-12-394280-7.00004-X
Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome, The Journal of Molecular Diagnostics, vol.10, issue.4, pp.293-300, 2008. ,
DOI : 10.2353/jmoldx.2008.080031
Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer), New England Journal of Medicine, vol.352, issue.18, pp.1851-1860, 2005. ,
DOI : 10.1056/NEJMoa043146
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting Highlights and Bethesda Guidelines, JNCI Journal of the National Cancer Institute, vol.89, issue.23 ,
DOI : 10.1093/jnci/89.23.1758
Quasimonomorphic Mononucleotide Repeats for High-Level Microsatellite Instability Analysis, Disease Markers, vol.20, issue.4-5, pp.251-257, 2004. ,
DOI : 10.1155/2004/159347
Multipopulation Analysis of Polymorphisms in Five Mononucleotide Repeats Used to Determine the Microsatellite Instability Status of Human Tumors, Journal of Clinical Oncology, vol.24, issue.2 ,
DOI : 10.1200/JCO.2005.02.7227
HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer, J Med Genet, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01427452
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer, New England Journal of Medicine, vol.349, issue.3, pp.247-257, 2003. ,
DOI : 10.1056/NEJMoa022289
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer, Journal of Clinical Oncology, vol.28, issue.20, pp.3219-3226, 2010. ,
DOI : 10.1200/JCO.2009.27.1825
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy, JNCI Journal of the National Cancer Institute, vol.103, issue.11, pp.863-875, 2011. ,
DOI : 10.1093/jnci/djr153
Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer, Journal of Clinical Oncology, vol.29, issue.10, pp.1261-1270, 2011. ,
DOI : 10.1200/JCO.2010.30.1366
in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial, Journal of Clinical Oncology, vol.28, issue.3, pp.466-474, 2010. ,
DOI : 10.1200/JCO.2009.23.3452
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin, Annals of Oncology, vol.21, issue.4, pp.772-780, 2010. ,
DOI : 10.1093/annonc/mdp383
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study, Journal of the National Cancer Institute, vol.108, issue.7, p.438, 2016. ,
DOI : 10.1093/jnci/djv438
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis, Nature Medicine, vol.58, issue.10, pp.1283-1289, 2011. ,
DOI : 10.1038/nature05378
Patients With Colorectal Tumors With Microsatellite Instability and??Large Deletions in HSP110 T17 Have Improved Response to 5-Fluorouracil???Based Chemotherapy, Gastroenterology, vol.146, issue.2, pp.401-411 ,
DOI : 10.1053/j.gastro.2013.10.054
Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial, Journal of Clinical Oncology, vol.34, 2016. ,
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-2666, 2005. ,
DOI : 10.1056/NEJMoa051424
Regulatory T Lymphocytes Are Associated with Less Aggressive Histologic Features in Microsatellite-Unstable Colorectal Cancers, PLoS ONE, vol.355, issue.4, 2013. ,
DOI : 10.1371/journal.pone.0061001.t002
Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer, Cancer Immunology, Immunotherapy, vol.348, issue.5, pp.653-661, 2010. ,
DOI : 10.4049/jimmunol.168.9.4272
Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study., Journal of Clinical Oncology, vol.34, issue.4_suppl, 2016. ,
DOI : 10.1200/jco.2016.34.4_suppl.553
URL : https://hal.archives-ouvertes.fr/hal-01490356
Towards the introduction of the ???Immunoscore??? in the classification of malignant tumours, The Journal of Pathology, vol.39, issue.2, pp.199-209, 2014. ,
DOI : 10.1016/j.immuni.2013.10.003
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability, Immunity, vol.44, issue.3, pp.698-711, 2016. ,
DOI : 10.1016/j.immuni.2016.02.025
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients, Journal of Clinical Oncology, vol.34, 2016. ,
Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy, Anticancer Res, vol.23, pp.1773-1777, 2003. ,
Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer, Anticancer research, vol.27, pp.2715-2719, 2007. ,
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, British Journal of Cancer, vol.154, issue.2, pp.266-273, 2009. ,
DOI : 10.1200/JCO.2003.03.123
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, vol.28, issue.15 suppl, pp.4623-4632, 2011. ,
DOI : 10.1200/JCO.2009.23.3452
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels, Journal of Clinical Oncology, vol.34, issue.18, pp.2141-2147, 2016. ,
DOI : 10.1200/JCO.2015.65.1067
Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy., Oncotarget, vol.5, issue.19, p.9199, 2014. ,
DOI : 10.18632/oncotarget.2374
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma, Cell Reports, vol.15, issue.4, pp.857-865, 2016. ,
DOI : 10.1016/j.celrep.2016.03.075
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy, Cancer Research, vol.75, issue.17, pp.3446-3455 ,
DOI : 10.1158/0008-5472.CAN-14-3051
Interobserver variability in the evaluation of mismatch repair protein immunostaining, Human Pathology, vol.41, issue.10, pp.1387-1396, 2010. ,
DOI : 10.1016/j.humpath.2010.03.003
Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting, The American Journal of Surgical Pathology, vol.32, issue.8, pp.1246-1251, 2008. ,
DOI : 10.1097/PAS.0b013e31816401bb
Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Diagnostics, JNCI Journal of the National Cancer Institute, vol.99, issue.4, pp.291-299, 2007. ,
DOI : 10.1093/jnci/djk051
The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations, Gastroenterology, vol.135, issue.2, pp.419-428, 2008. ,
DOI : 10.1053/j.gastro.2008.04.026
Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with highfrequency microsatellite instability, Oncol Rep, vol.21, pp.1577-1583, 2009. ,
BRAF mutation in sporadic colorectal cancer and Lynch syndrome, Virchows Archiv, vol.61, issue.5, pp.613-621, 2013. ,
DOI : 10.1136/gutjnl-2011-300041
A Prospective, Multicenter, Population-Based Study of BRAF Mutational Analysis for Lynch Syndrome Screening, Clinical Gastroenterology and Hepatology, vol.6, issue.2, pp.206-214, 2008. ,
DOI : 10.1016/j.cgh.2007.10.011
methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification, Journal of Medical Genetics, vol.49, issue.3, pp.151-157 ,
DOI : 10.1136/jmedgenet-2011-100714
A Modified Lynch Syndrome Screening Algorithm in Colon Cancer: BRAF Immunohistochemistry Is Efficacious and Cost Beneficial, American Journal of Clinical Pathology, vol.143, issue.3, pp.336-343 ,
DOI : 10.1309/AJCP4D7RXOBHLKGJ
MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas, The American Journal of Surgical Pathology, vol.40, issue.10, 2016. ,
DOI : 10.1097/PAS.0000000000000695
Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation, International Journal of Cancer, vol.27, issue.Suppl; abstr 90, pp.2075-2084, 2011. ,
DOI : 10.1200/JCO.2009.24.6744
Les pts avec un CCRm dMMR et/ou MSI ont été identifiés rétrospectivement. Le statut dMMR et MSI a été confirmé de manière centralisée. Les critères d'exclusion étaient : absence de matériel tumoral disponible, tumeur pMMR (proficient MMR) et MSS (MS stables) Les statuts RAS, BRAF et l ,
La médiane de survie globale des SP à partir du stade métastatique était inférieure à celle des LS (18.5 vs 40.7 mois, P=.004) La survie sans progression médiane en 1 e ligne métastatique (N=89) était de 6, et 9.2 mois (P=.65). La survie sans maladie des cas métastatiques réséqués ,